来自官方财务报表的收入、利润与现金流历史。
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| 总收入 | ₹167.1B | ₹131.5B | ₹116.4B | ₹114.3B | — |
| 毛利 | ₹116.0B | ₹83.9B | ₹67.6B | ₹68.5B | — |
| 营业利润（EBIT） | ₹40.2B | ₹18.7B | ₹6.3B | ₹10.8B | — |
| 净利 | ₹13.6B | ₹10.5B | (₹15.0B) | ₹3.0B | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 GLENMARK 交互式查看器。 /companies/us/GLENMARK
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms